Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy. Neuroblastoma as a model.

N K Cheung1

  • 1Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York.

Pediatric Clinics of North America
|April 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prediction model for return to work after injury in Hong Kong: abridged secondary publication.

Hong Kong medical journal = Xianggang yi xue za zhi·2022
Same author

Trajectory of functional outcome and health status after moderate-to-major trauma in Hong Kong: A prospective 5 year cohort study.

Injury·2019
Same author

Trauma team activation criteria and outcomes of geriatric trauma: 10 year single centre cohort study.

The American journal of emergency medicine·2018
Same author

Vascularized Tissue-Engineered Model for Studying Drug Resistance in Neuroblastoma.

Theranostics·2017
Same author

Acute myeloid leukemia targets for bispecific antibodies.

Blood cancer journal·2017
Same author

Acute myeloid leukemia targets for bispecific antibodies.

Blood cancer journal·2017
Same journal

Barriers, Breakthroughs, and the Future of Pediatric Dermatologic Care.

Pediatric clinics of North America·2026
Same journal

Advancing Pediatric Dermatology: Innovations in Care and Access.

Pediatric clinics of North America·2026
Same journal

No Child Left Behind: Advancing Access in Pediatric Dermatology, a 4-Year, Single-Center Experience.

Pediatric clinics of North America·2026
Same journal

Telemedicine and Access to Pediatric Dermatology Care.

Pediatric clinics of North America·2026
Same journal

Inequitable Reimbursement for Pediatric Providers: A Review of Structural Factors that Disincentivize the Care of Children.

Pediatric clinics of North America·2026
Same journal

Medical Photography's Power to Change Medical Care.

Pediatric clinics of North America·2026
See all related articles

Aggressive treatments and immunotherapy show promise for stage IV neuroblastoma. Immunotherapy, using monoclonal antibodies and enhanced immune cells, may permanently eradicate remaining cancer cells after initial treatment.

Area of Science:

  • Pediatric Oncology
  • Immunology
  • Cancer Therapy

Background:

  • Stage IV neuroblastoma is a challenging pediatric cancer requiring aggressive treatment strategies.
  • Complete remissions can be achieved with combined chemotherapy and radiotherapy.
  • Residual microscopic disease remains a significant challenge for permanent eradication.

Purpose of the Study:

  • To explore the potential of immunotherapy in eradicating microscopic residual disease in stage IV neuroblastoma.
  • To highlight the tumor-specific mechanisms of immunotherapy for neuroblastoma.
  • To discuss novel immunotherapeutic approaches for durable cancer remission.

Main Methods:

  • Review of current therapeutic strategies including chemotherapy and radiotherapy.
  • Discussion of immunotherapy mechanisms, including monoclonal antibodies and cytokine-enhanced leukocytes.

Related Experiment Videos

  • Exploration of ex vivo activated and genetically manipulated autologous immune cells.

    • Main Results:

    • Immunotherapy demonstrates tumor specificity and potential for high concentration accumulation in neuroblastomas.
    • Monoclonal antibodies can trigger complement activation and localized inflammation.
    • Hematopoietic factors and cytokines can augment tumoricidal leukocyte activity.

    Conclusions:

    • Immunotherapy holds significant promise for eradicating microscopic residual disease in stage IV neuroblastoma.
    • Combining immunotherapy with conventional therapies may lead to permanent tumor eradication.
    • Further understanding of tumor-host immunobiology will optimize combination treatment strategies.